For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Exenatide
Illustration for Exenatide

THE PEPSRADAR ENCYCLOPEDIA

Exenatide

Glucose-dependent insulin signaling

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Exenatide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (Byetta) on DailyMed ↗

What is Exenatide?

Exenatide is an incretin medicine used in type 2 diabetes. Short-acting and extended-release products need to be distinguished when reading evidence.

Biological role or research focus

Glucose-dependent insulin signaling.

Its established clinical context is type 2 diabetes, with formulation-specific precautions.

Role reference: MedlinePlus · Exenatide ↗

Names you may encounter

Byetta · Bydureon

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
GLP-1 receptor agonist
Main research area
Type 2 diabetes
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Exenatide ↗

Quick answers

Is Exenatide FDA approved?
Yes. Byetta (NDA 021919 listed as prescription) for type 2 diabetes. Source ↗
Is Exenatide safe?
Approved GLP-1 drug for type 2 diabetes; stomach upset is common, with risks of pancreatitis, low blood sugar alongside other diabetes drugs, and rare immune-related low platelets. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Exenatide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
Has the FDA taken action over Exenatide?
Yes. Our records list 1 FDA action naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research
StudyTypePopulation / model
EXSCEL (2017)Human randomized trial14,752 adults with type 2 diabetes.
Phase 3 Parkinson disease trial (2025)Human phase 3 randomized trial194 people aged 25–80 with Parkinson disease were randomized equally at six UK hospitals; 188 had follow-up data included in analyses.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2017

EXSCEL

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Population / model
14,752 adults with type 2 diabetes.
Study design
Once-weekly exenatide versus placebo; cardiovascular outcomes followed over a median 3.2 years.
Main finding
The main cardiovascular composite occurred in 11.4% versus 12.2%; hazard ratio 0.91 (95% CI 0.83–1.00). Noninferiority was met, but superiority was not (P=0.06).
How to read it
The 0.8-percentage-point observed event difference is descriptive. The primary superiority test was not significant, so EXSCEL cannot be presented as a proven cardiovascular-event reduction.
Limits & context
Meeting a cardiovascular safety criterion is different from proving cardiovascular benefit. Results concern the once-weekly preparation and should not be relabeled as an obesity trial.

Source: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. ↗

Human phase 3 randomized trial · 2025

Phase 3 Parkinson disease trial

Did extended-release exenatide slow Parkinson motor progression?

Population / model
194 people aged 25–80 with Parkinson disease were randomized equally at six UK hospitals; 188 had follow-up data included in analyses.
Study design
Double-blind placebo comparison for 96 weeks on top of dopaminergic treatment. The primary motor score was assessed off dopaminergic medication.
Main finding
MDS-UPDRS part III off-medication scores worsened by 5.7 points with exenatide versus 4.5 with placebo. Adjusted treatment coefficient: 0.92 (95% CI −1.56 to 3.39; P=0.47). At least one serious adverse event occurred in 9% versus 11%.
How to read it
The larger phase 3 study did not support a disease-modifying effect in this population. Earlier mechanistic or small-study signals should be read alongside this negative result.
Limits & context
This result concerns exenatide, the studied population, and the specified endpoint. It does not prove that every GLP-1 agent has identical neurological effects. A nonsignificant result also does not prove exact equivalence or absence of rare harms.

Source: Exenatide phase 3 Parkinson trial · The Lancet · 2025 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

58 registered studies name Exenatide as an intervention among the 100 most recently updated of 381 search results; 5 are recruiting or under way, 0 have not started recruiting yet, 41 completed and 12 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT05663515 · AstraZeneca
Recruiting2024-09-3024000
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
NCT02860923 · University Hospital, Bordeaux
CompletedPhase 32017-01-1142
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
NCT02042664 · Assistance Publique Hopitaux De Marseille
CompletedPhase 32011-0144
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
NCT04232969 · University College, London
CompletedPhase 32020-01-20194
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
NCT05482789 · Maisa N. Feghali, MD
RecruitingPhase 42023-04-1213
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
NCT07347080 · The First Affiliated Hospital of Henan University of Science and Technology
RecruitingEarly phase 12026-01-209
Exenatide for Smoking Cessation and Prevention of Weight Gain
NCT05610800 · The University of Texas Health Science Center, Houston
CompletedPhase 22022-12-07140
Exenatide For Reducing the Reinforcing Effects of Cocaine
NCT06252623 · Christopher D. Verrico
WithdrawnPhase 12024-08-010

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 58 listed studies.

Search additional PubMed records ↗

Risks & interactions

Approved GLP-1 drug for type 2 diabetes; stomach upset is common, with risks of pancreatitis, low blood sugar alongside other diabetes drugs, and rare immune-related low platelets.

Human safety data: FDA label

This entry follows the Byetta label, which has no boxed warning; other exenatide products have separate labels that may differ. Safety comes from controlled diabetes trials and postmarketing reports.

Take extra care with: Blood thinners or bleeding problemsDiabetes or blood-sugar medicinesKidney problems

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • Past severe allergic reaction to exenatide or any ingredient
  • Past drug-induced immune low platelet count (thrombocytopenia) from exenatide
  • Not recommended with severe gastroparesis (label warning)

Interactions

  • Insulin or sulfonylureas: higher risk of low blood sugar
  • Warfarin: reports of increased INR, sometimes with bleeding
  • Oral medicines such as acetaminophen: slowed stomach emptying can delay absorption

Serious risks

  • Acute pancreatitis, including fatal forms
  • Immune-related low platelets causing serious, possibly fatal, bleeding
  • Kidney injury from dehydration due to vomiting or diarrhea
  • Antibodies that may weaken blood sugar control
  • Gallbladder disease; serious allergic reactions
  • Inhaling stomach contents during anesthesia or deep sedation

Common side effects

  • nausea
  • low blood sugar
  • vomiting
  • diarrhea
  • feeling jittery
  • dizziness
  • headache
  • indigestion

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Byetta (exenatide) prescribing information ↗

Key precautions

Gastrointestinal effects, pancreatitis concerns, kidney-related precautions, and medication interactions matter. Product-specific warnings may differ between preparations, so the exact label is essential.

Source: MedlinePlus · Exenatide ↗

Regulatory status

U.S. FDA approval
Approved
Byetta (NDA 021919 listed as prescription) for type 2 diabetes. Bydureon, Bydureon BCise and the earlier Byetta application (NDA 021773) are listed as discontinued. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

FDA actions

  • FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source

Other notes

  • Exenatide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

The medication reference describes diabetes care alongside diet and exercise. EXSCEL specifically tested a once-weekly preparation for cardiovascular outcomes; its safety finding should not be relabeled as a demonstrated superiority benefit.

Source: MedlinePlus · Exenatide ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).

Mechanism & research rationale

It promotes insulin release when glucose is elevated. This supports glucose management, but does not by itself establish a reduction in cardiovascular events.

Source: MedlinePlus · Exenatide ↗

Molecular structure

Exenatide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 45588096 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • Its established clinical context is type 2 diabetes, with formulation-specific precautions.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Did EXSCEL prove fewer cardiovascular events?

It met the prespecified noninferiority safety test, but not the superiority test.

Source: MedlinePlus · Exenatide ↗

Can all exenatide products be substituted by name?

No. Release characteristics and product instructions differ.

Source: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. ↗

Can a promising GLP-1 mechanism establish treatment for Parkinson disease?

No. Laboratory rationale must be tested against clinical outcomes. The 2025 exenatide phase 3 trial did not demonstrate slowed motor progression at 96 weeks.

Source: Exenatide phase 3 Parkinson trial · The Lancet · 2025 ↗

Can the lixisenatide result replace the exenatide result?

No. These are different medicines, populations, durations, and assessment conditions. Separate trial results should remain attached to the studied compound.

Source: Exenatide phase 3 Parkinson trial · The Lancet · 2025 ↗

How complete is this evidence review?

This profile summarizes selected NLM abstracts and linked medicine information. It is not a systematic review. Full-text verification and a comprehensive search have not been done, and this summary has not been reviewed by a medical professional.

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Exenatide

Download illustration ↓Source record ↗
Exenatide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.